Japan approves the first iPS cell treatment of spinal cord injury clinical trial

February 21, 2019 Source: Health News Network

Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];

On the 18th, the Japanese Ministry of Health, Labor and Welfare approved the first clinical trial in the world to treat spinal cord injury using induced pluripotent stem cells (iPS cells). If all goes well, the trial is expected to begin during the year.

According to a number of Japanese media reports, the trial proposed by Keio University in Japan will soon be officially approved by the Minister of Health, Labour and Welfare of Japan. According to the plan, the research team led by Prof. Okano Eiji will recruit 4 volunteers over the age of 18 and spinal cord injury for 2 weeks to 4 weeks. The specific method is to inject the neural stem cells from the iPS cell culture into the patient. To repair the damaged spinal cord.

The spinal cord is an important part of the central nervous system of the human body. After the spinal cord is damaged, the nervous system cannot work normally. Patients often suffer from paralysis. In Japan alone, there are more than 100,000 people with spinal cord injury. Repairing the damaged spinal cord has always been a medical problem. Once successful, iPS cell therapy will bring new hope to patients with spinal cord injuries in sports or traffic accidents.

iPS cells are stem cells that are "reprogrammed" by mature somatic cells and have similar differentiation potential to embryonic stem cells, but the acquisition method is relatively simple, while avoiding the ethical problems in embryonic stem cell research, so it is It is considered to have great application value.

Japan has so far approved a number of clinical trials for the treatment of diseases involving iPS cells. For example, Kyoto University in Japan announced in November last year that it has transplanted neural progenitor cells cultured from iPS cells into the brain of a Parkinson's disease patient. The recovery of the patient is good, but the surgical effect and safety need long-term observation.

Anesthesia and Breath Disposables

Central Venous Catheter,Hemodialysis Catheter,Blood Pressure Transducer,Phripheral Inerted Central Catheter,Artery Compression Device Sampler,Infusion Pump

Anesthesia Medical Co., Ltd. , https://www.jssinoanesthesias.com